This series of graphics describes the different mechanisms of action that have been proposed for this monoclonal drug therapy. The aim of the therapy is to deplete B cells in order to interrupt several key aspects of an ongoing autoimmune response.

View associated Case Study – A 7 year old with severe muscle weakness and difficulty walking

Download Rituximab Mode of Action Guide

CD20 induced Apoptosis

Classical complement activation








C3B Opsonisation and Phagacytosis

LgG Opsonisation and Phagocytosis








Antibody Dependent cell cytotoxicity by natural killer cells

International Union of Immunological SocietiesUniversity of South AfricaInstitute of Infectious Disease and Molecular MedicineElizabeth Glazer Pediatric Aids Foundation